Shares of Resmed (ASX:RMD) fell 2% on recent Tuesday trade after it received US Food and Drug Administration clearance for a medical device that provides personalized comfort settings to help people with obstructive sleep apnea stay on Continuous Positive Airway Pressure (CPAP) therapy, according to a Monday statement.
The device will launch in early 2026, the statement said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.